NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

think for a moment if the opposite were true and the "removal" from the trial caused the trial to FAIL, would you still be saying the same thing - that's how the cookie crumbles? Ie

I have seriously no idea what you are talking about. You are describing an alternate reality here.

DCVAX is most likely not as efficient on IDH mutant as its is on other types. Why is that? Well turns out its not because IDH mutant is not GBM, not according to NWBO but to the WHO. Thus DCVAX L is way more efficient on what the WHO, not NWBO the WHO calls GBM than previously thought.

I cant understand anyone, other than the shorts, having a problem with that?